KRMD director receives 5,357-share stock grant

FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.

KORU Medical Systems director R. John Fletcher received a grant of 5,357 shares of Common Stock at $4.20 per share. This was a compensation-related award rather than an open-market purchase. After the grant, he directly owns 232,157 shares, indicating the award is a relatively small addition to his existing position.

Insider Trade Summary

Grant/Award: 5,357 shares

Grant/Award 1 txn

Insider FLETCHER R JOHN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,357	$4.20	$22K

Holdings After Transaction: Common Stock — 232,157 shares (Direct)

Key Figures

Shares granted: 5,357 shares Grant price: $4.20 per share Post-transaction holdings: 232,157 shares +1 more

4 metrics

Shares granted 5,357 shares Common Stock grant to R. John Fletcher

Grant price $4.20 per share Reported transaction price for the award

Post-transaction holdings 232,157 shares Direct ownership after the grant

Transaction date July 1, 2026 Date of Common Stock grant

Key Terms

Common Stock, Grant, award, or other acquisition, Form 4, Chairman of the Board

4 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Chairman of the Board financial

"other: "Chairman of the Board""

Chairman of the board is the person who leads a company’s board of directors, setting meeting agendas, guiding discussions and ensuring the board supervises management’s strategy and risk decisions. Investors care because the chair’s leadership and style influence how well shareholder interests are protected, how quickly strategic choices are made, and the company’s overall accountability—like a team captain shaping group performance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KRMD director R. John Fletcher report?

R. John Fletcher reported receiving a grant of 5,357 shares of KORU Medical Systems Common Stock. The award was recorded at $4.20 per share and classified as a grant, award, or other acquisition rather than an open-market buy or sell transaction.

Was the KRMD Form 4 transaction an open-market buy or a share grant?

The KRMD Form 4 shows a share grant, not an open-market purchase. The transaction code is “A,” described as a grant, award, or other acquisition, indicating compensation-related issuance of 5,357 Common Stock shares at $4.20 per share to the reporting person.

How many KRMD shares does R. John Fletcher hold after this Form 4?

After the reported grant, R. John Fletcher holds 232,157 shares of KORU Medical Systems Common Stock directly. This total includes the 5,357-share award disclosed in the Form 4 and reflects his direct ownership position following the transaction date of July 1, 2026.

What is the significance of transaction code “A” on the KRMD Form 4?

Transaction code “A” signifies a grant, award, or other acquisition of securities. For KORU Medical Systems, it indicates that 5,357 shares were awarded to R. John Fletcher as compensation or similar non-market consideration, rather than purchased in open-market trading.

What price per share was used for the KRMD stock grant on this Form 4?

The KRMD Form 4 lists a transaction price of $4.20 per share for the grant. This price is used for reporting the 5,357-share award of Common Stock to R. John Fletcher and helps indicate the notional value of this compensation-related transaction.

Does the KRMD Form 4 show any stock sales or dispositions by R. John Fletcher?

The KRMD Form 4 does not show any stock sales or dispositions by R. John Fletcher. It reports only one transaction: an acquisition of 5,357 Common Stock shares coded as a grant, award, or other acquisition, leaving his direction as purely acquisitive in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 05:18 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FLETCHER R JOHN

(Last) (First) (Middle)

C/O KORU MEDICAL SYSTEMS, INC.

100 CORPORATE DRIVE

(Street)

MAHWAH NEW JERSEY 07430

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Chairman of the Board

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		A		5,357	A	$4.2	232,157	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.

	/s/ Thomas Adams - Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)